Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia
The question of how and when to communicate potential risks associated with new drugs has remained an important focus of tension between the pharmaceutical industry and regulatory entities, such as the American Food and Drug Administration. Recently there has been widespread concern related to the c...
Guardado en:
Autores principales: | , |
---|---|
Lenguaje: | Spanish / Castilian |
Publicado: |
Sociedad Médica de Santiago
2010
|
Materias: | |
Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000900017 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|